Evidence map›Paper›PMID 30138674›Full record

ReviewMethods (San Diego, Calif.)2019

Identifying and characterizing functional 3' nucleotide addition in the miRNA pathway.

A Maxwell Burroughs, Yoshinari Ando

Open access · hybridAbstract readReview
In one paragraph

Review in Methods (San Diego, Calif.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

A Maxwell BurroughsNational Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, MD, USA. Electronic address: max.burroughs@nih.gov.
Yoshinari AndoDivision of Cancer Stem Cell, National Cancer Center Research Institute, Tokyo, Japan.
National Center for Biotechnology Information · US

Funding

Intramural NIH HHS Z99 LM999999
6 · The paper itself

Abstract

Over the past decade, modifications to microRNAs (miRNAs) via 3' end nucleotide addition have gone from a deep-sequencing curiosity to experimentally confirmed drivers of a range of regulatory activities. Here we overview the methods that have been deployed by researchers seeking to untangle these diverse functional roles and include characterizing not only the nucleotidyl transferases catalyzing the additions but also the nucleotides being added, and the timing of their addition during the miRNA pathway. These methods and their further development are key to clarifying the diverse and sometimes contradictory functional findings presently attributed to these nucleotide additions.

Indexed as

Computational BiologyGenome, HumanHumansMicroRNAsRNA 3' End ProcessingSequence Analysis, RNAMicroRNAs

Identifiers

PMID30138674
PMCPMC6311138
OpenAlexW2888292967

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.